The research of Stephen M. Ansell, M.D., Ph.D., is focused on understanding the biology of B-cell malignancies (including Hodgkin's lymphoma Waldenstrom's macroglobulinemia and non-Hodgkin's lymphoma) and to explore the role of the tumor microenvironment in supporting cancer cell growth and survival. The goal of his program is to translate this knowledge into new treatment approaches for patients.
- T-cell activation and T-cell exhaustion. Dr. Ansell's lab studies why the immune response to cancer is suppressed.
- Tumor-associated macrophages and monocytes. This research seeks to understand the role of phagocytic cells in the tumor.
- The bone marrow microenvironment in Waldenstrom's macroglobulinemia. Dr. Ansell's lab is studying the role of cytokines and immunologically active signals in activating or suppressing tumors and promoting immunoglobulin production.
Significance to patient care
Dr. Ansell's research has contributed to the use of immune checkpoint therapy in lymphomas. He led the clinical trial that resulted in the approval of nivolumab (Opdivo) for Hodgkin's lymphoma.
- Chair, Scientific Advisory Committee of the International Waldenstrom's Macroglobulinemia Foundation, 2015-present
- Editorial board, Journal of Clinical Oncology, 2015-present
- Member, Scientific Committee of the Leukemia & Lymphoma Society, 2015-present
- Chair, Mayo Clinic Lymphoma Group, 2014-present
- Associate editor, American Journal of Hematology, 2011-present